Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS)

Vaccine

Volumn 29, Issue 45, 2011, Pages 7949-7959

  Poethko Müller, Christina ^a   Mankertz, Annette ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Age at first vaccination; Health survey; IgG measles antibodies; Immunity; Seroprevalence; Vaccination; Waning

Indexed keywords

IMMUNOGLOBULIN G; MEASLES VACCINE;

ADOLESCENT; ARTICLE; CHILD; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GERMAN HEALTH INTERVIEW AND EXAMINATION SURVEY FOR CHILDREN AND ADOLESCENTS; GERMANY; HEALTH SURVEY; HUMAN; IMMIGRATION; MEASLES; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SERODIAGNOSIS; VACCINATION;

ADOLESCENT; ANTIBODIES; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE ERADICATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MEASLES; MODELS, STATISTICAL; SEROEPIDEMIOLOGIC STUDIES;

EID: 80053629547     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.081     Document Type: Article

References (82)

1. Ramsay M. A strategic framework for the elimination of measles in European Region 1999, The Expanded Programme on Immunization in the European Region of WHO (EUR/ICD/CMDS 01 01 05), p. 1-26.
2. Tischer A., Santibanez S., Siedler A., Heider A., Hengel H. Laboratory investigations are indispensable to monitor the progress of measles elimination-results of the German Measles Sentinel 1999-2003. J Clin Virol 2004, 31(November (3)):165-178.
3. Mankertz A., Mihneva Z., Gold H., Baumgarte S., Baillot A., Helble R., et al. Spread of measles virus D4-Hamburg in Europe. Eur Infect Dis 2011, 17(August (8)):1396-1401.
4. Batzing-Feigenbaum J., Pruckner U., Beyer A., Sinn G., Dinter A., Mankertz A., et al. Spotlight on measles 2010: preliminary report of an ongoing measles outbreak in a subpopulation with low vaccination coverage in Berlin, Germany, January-March 2010. Euro Surveill 2010, 15(13).
5. Roggendorf H., Mankertz A., Kundt R., Roggendorf M. Spotlight on measles 2010: measles outbreak in a mainly unvaccinated community in Essen, Germany, March-June 2010. Euro Surveill 2010, 15(July (26)).
6. Siedler A., Mankertz A., Ahlemeyer G., Feil F., Hornig A., Scharkus S., et al. Closer to the goal-efforts in measles elimination in Germany 2010. J Infect Dis 2011, 204(Suppl. 1):S373-380.
7. Poethko-Müller C., Ellert U., Kuhnert R., Neuhauser H., Schlaud M., Schenk L. Vaccination coverage against measles in German-born and foreign-born children and identification of unvaccinated subgroups in Germany. Vaccine 2009, 27:2563-2569.
8. Wichmann O., Hellenbrand W., Sagebiel D., Santibanez S., Ahlemeyer G., Vogt G., et al. Large measles outbreak at a German public school 2006. Pediatr Infect Dis J 2007, 26(September (9)):782-786.
9. Wichmann O., Siedler A., Sagebiel D., Hellenbrand W., Santibanez S., Mankertz A., et al. Further efforts needed to achieve measles elimination in Germany: results of an outbreak investigation. Bull World Health Organ 2009, 87(February (2)):108-115.
10. Kurth B.M., Kamtsiuris P., Holling H., Schlaud M., Dolle R., Ellert U., et al. The challenge of comprehensively mapping children's health in a nation-wide health survey: design of the German KiGGS-Study. BMC Public Health 2008, 8:196.
11. Kurth B., Kamtsiuris P., Hölling H., Schlaud M., Dölle R., Ellert U., et al. The challenge of comprehensively mapping children's health in a nation-wide health survey: design and first results of the German KiGGS-Study 2008, BioMed Central Public Health, p. 196.
12. Vaidya S.R., Brown D.W., Jin L., Samuel D., Andrews N., Brown K.E. Development of a focus reduction neutralization test (FRNT) for detection of mumps virus neutralizing antibodies. J Virol Methods 2010, 163(January (1)):153-156.
13. Ho C.K., Babiuk L.A. A new plaque system for canine distemper: characteristics of the green strain of canine distemper virus. Can J Microbiol 1979, 25(June (6)):680-685.
14. Lee M.S., Chien L.J., Yueh Y.Y., Lu C.F. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997. Vaccine 2001, 19(September (32)):4644-4651.
15. Vandermeulen C., Mathieu R., Geert L.R., Pierre V.D., Karel H. Long-term persistence of antibodies after one or two doses of MMR-vaccine. Vaccine 2007, 25(September (37-38)):6672-6676.
16. Pebody R.G., Gay N.J., Hesketh L.M., Vyse A., Morgan-Capner P., Brown D.W., et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002, 20(January (7-8)):1134-1140.
17. Cohen B.J., Parry R.P., Doblas D., Samuel D., Warrener L., Andrews N., et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 2006, 131(February (2)):209-212.
18. Brugha R., Ramsay M., Forsey T., Brown D. A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women. Epidemiol Infect 1996, 117(December (3)):519-524.
19. Christenson B., Bottiger M. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994, 12(February (2)):129-133.
20. Kacica M.A., Venezia R.A., Miller J., Hughes P.A., Lepow M.L. Measles antibodies in women and infants in the vaccine era. J Med Virol 1995, 45(February (2)):227-229.
21. van den Hof S., Berbers G.A.M., de Melker H.E., Conyn-van Spaendonck M.A.E. Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage. Vaccine 2000, 18:931-940.
22. Diez-Domingo J., Gil A., San-Martin M., Gonzalez A., Esteban J., Baldo J.M., et al. Seroprevalence of varicella among children and adolescents in Valencia, Spain. Reliability of the parent's reported history and the medical file for identification of potential candidates for vaccination. Hum Vaccines 2005, 1(September-October (5)):204-206.
23. Miller E., Hill A., Morgan-Capner P., Forsey T., Rush M. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 1995, 13(June (9)):799-802.
24. Theeten H., Hens N., Vandermeulen C., Depoorter A.M., Roelants M., Aerts M., et al. Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. Vaccine 2007, 4940-4948.
25. Mossong J., O'Callaghan C.J., Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 2000, 19(October (4-5)):523-529.
26. Pedersen I.R., Mordhorst C.H., Ewald T., von Magnus H. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland. Vaccine 1986, 4(September (3)):173-178.
27. Schwarzer S., Reibel S., Lang A.B., Struck M.M., Finkel B., Gerike E., et al. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 1998, 16(January-February (2-3)):298-304.
28. Kremer J.R., Schneider F., Muller C.P. Waning antibodies in measles and rubella vaccinees-a longitudinal study. Vaccine 2006, 24(March (14)):2594-2601.
29. Mossong J., Putz L., Schneider F. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study. Epidemiol Infect 2004, 132(January (1)):11-18.
30. Davidkin I., Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 1998, 16(December (20)):2052-2057.
31. Poethko-Müller C., Kuhnert R., Schlaud M. Vaccination coverage and predictors for vaccination level. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007, 50(May-June (5-6)):851-862.
32. Kalies H., Grote V., Schmitt H.J., Kries R. Immunisation status of children in Germany: temporal trends and regional differences. Eur J Pediatr 2006, 165(1):30-36.
33. Tischer A., Andrews N., Kafatos G., Nardone A., Berbers G., Davidkin I., et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiol Infect 2007, 135(July (5)):787-797.
34. Tischer A., Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000, 18(January (14)):1382-1392.
35. Diaz-Ortega J.L., Forsey T., Clements C.J., Milstien J. The relationship between dose and response of standard measles vaccines. Biologicals 1994, 22(March (1)):35-44.
36. Stokes J., Reilly C.M., Buynak E.B., Hilleman M.R. Immunologic studies of measles. Am J Hyg 1961, November (74):293-303.
37. Friedman M.G., Romanova S., Galil A., Sarov B., Dagan R. Comparison of a commercial ELISA kit and a neutralization assay for assessment of humoral immunity to measles virus. Serodiagnosis Immunother Infect Dis 1997, 8(3):131-135.
38. Ratnam S., Gadag V., West R., Burris J., Oates E., Stead F., et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995, 33(April (4)):811-815.
39. Cohen B.J., Doblas D., Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specific IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine 2008, 26(November (50)):6392-6397.
40. Tischer A., Gassner M., Richard J.L., Suter-Riniker F., Mankertz A., Heininger U. Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. J Clin Virol 2007, 38(March (3)):204-209.
41. Samb B., Aaby P., Whittle H.C., Seck A.M., Rahman S., Bennett J., et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995, 14(March (3)):203-209.
42. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990, 162(November (5)):1036-1042.
43. Ceyhan M., Kanra G., Erdem G., Kanra B. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age. Vaccine 2001, 19(August (31)):4473-4478.
44. Johnson C.E., Nalin D.R., Chui L.W., Whitwell J., Marusyk R.G., Kumar M.L. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics 1994, 93(June (6 Pt 1)):939-944.
45. Markowitz L.E., Albrecht P., Rhodes P., Demonteverde R., Swint E., Maes E.F., et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996, 97(January (1)):53-58.
46. Orenstein W.A., Markowitz L., Preblud S.R., Hinman A.R., Tomasi A., Bart K.J. Appropriate age for measles vaccination in the United States. Dev Biol Stand 1986, 65:13-21.
47. Gans H.A., Arvin A.M., Galinus J., Logan L., DeHovitz R., Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998, 280(August (6)):527-532.
48. Carson M.M., Spady D.W., Albrecht P., Beeler J.A., Thipphawong J., Barreto L., et al. Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J 1995, 14(January (1)):17-22.
49. Pabst H.F., Boothe P.M., Carson M.M. A comparison of alternate immunization regimes for measles in vaccinated populations. Vaccine 1999, 17(January (2)):182-192.
50. Klinge J., Lugauer S., Korn K., Heininger U., Stehr K. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine 2000, 18(July (27)):3134-3140.
51. Garly M.L., Bale C., Martins C.L., Monteiro M., George E., Kidd M., et al. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 2001, 19(February (15-16)):1951-1959.
52. Zanetta R.A., Amaku M., Azevedo R.S., Zanetta D.M., Burattini M.N., Massad E. Optimal age for vaccination against measles in the State of Sao Paulo, Brazil, taking into account the mother's serostatus. Vaccine 2001, 20(October (1-2)):226-234.
53. Black F.L., Berman L.L., Libel M., Reichelt C.A., Pinheiro F.D., Travassos da Rosa A., et al. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull World Health Organ 1984, 62(2):315-319.
54. Wilkins J., Wehrle P.F. Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. J Pediatr 1979, 94(June (6)):865-869.
55. Stetler H.C., Orenstein W.A., Bernier R.H., Herrmann K.L., Sirotkin B., Hopfensperger D., et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 1986, 77(April (4)):471-476.
56. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A.C., Arvin A., Griffin D.E. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007, 196(November (9)):1339-1345.
57. Kumar M.L., Johnson C.E., Chui L.W., Whitwell J.K., Staehle B., Nalin D. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers. Vaccine 1998, 16(December (20)):2047-2051.
58. Green M.S., Shohat T., Lerman Y., Cohen D., Slepon R., Duvdevani P., et al. Sex differences in the humoral antibody response to live measles vaccine in young adults. Int J Epidemiol 1994, 23(October (5)):1078-1081.
59. Aaby P., Martins C., Bale C., Garly M.L., Rodrigues A., Biai S., et al. Sex differences in the effect of vaccines on the risk of hospitalization due to measles in Guinea-bissau. Pediatr Infect Dis J 2010, 29(April (4)):324-328.
60. Knudsen K.M., Aaby P., Whittle H., Rowe M., Samb B., Simondon F., et al. Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol 1996, 25(June (3)):665-673.
61. Khalil M.K., Al-Mazrou Y.Y., Al-Ghamdi Y.S., Tumsah S., Al-Jeffri M., Meshkhas A. Effect of gender on reporting of MMR adverse events in Saudi Arabia. East Mediterr Health J 2003, 9(January-March (1-2)):152-158.
62. Rhodes K., Markham R.L., Maxwell P.M., Monk-Jones M.E. Immunoglobulins and the X-chromosome. Br Med J 1969, 3(August (5668)):439-441.
63. Martins C., Bale C., Garly M.L., Rodrigues A., Lisse I.M., Andersen A., et al. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. Vaccine 2009, 27(August (38)):5220-5225.
64. Sun W.Y., Sangweni B., Butts G., Merlino M. Comparisons of immunisation accessibility between non-US born and US-born children in New York City. Public Health 1998, 112(November (6)):405-408.
65. Waldhoer T., Haindinger G., Vutue C., Haschke F., Plank R. The impact of sociodemographic variables of immunization coverage of children. Eur J Epidemiol 1997, 12:145-149.
66. Chu S.Y., Barquer L.E., Smith P.J. Racial/ethnic disparities in preschool immunizations: United States, 1996-2001. Am J Public Health 2004, 94:973-977.
67. Borràs E., Domínguez A., Batalla J., Torner N., Cardeñosa N., Nebot M., et al. Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 2007, 25(April (16)):3240-3243.
68. van der Wal M.F., Diepenmaat A.C., Pel J.M., Hirasing R.A. Vaccination rates in a multicultural population. Arch Dis Child 2005, 90(January (1)):36-40.
69. Coovadia H.M., Wesley A., Hammond M.G., Kiepiela P. Measles, histocompatibility leukocyte antigen polymorphism, and natural selection in humans. J Infect Dis 1981, 144(August (2)):142-147.
70. Galil K., Singleton R., Levine O.S., Fitzgerald M.A., Bulkow L., Getty M., et al. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 1999, 179(January (1)):101-106.
71. Hayney M.S., Poland G.A., Jacobson R.M., Schaid D.J., Lipsky J.J. The influence of the HLA-DRB1*13 allele on measles vaccine response. J Investig Med 1996, 44(June (5)):261-263.
72. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Pankratz V.S., Poland G.A. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: findings and implications for vaccine design. Vaccine 2007, 25(April (16)):3090-3100.
73. Poland G.A., Jacobson R.M., Colbourne S.A., Thampy A.M., Lipsky J.J., Wollan P.C., et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 1999, 17(March (11-12)):1525-1531.
74. Poland G.A., Jacobson R.M., Schaid D., Moore S.B., Jacobsen S.J. The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine 1998, 16(November (19)):1869-1871.
75. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009, 10(May (5)):837-852.
76. Poland G.A., Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., et al. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 2001, 20(November (3-4)):430-438.
77. Poland G.A., Sohni Y., Domanico M., Kroning C.M., DeGoey S.R., Jimale M., et al. High frequency of HLA-A*0103 allele in a Somali population. Hum Immunol 2001, 62(February (2)):197-200.
78. Rager-Zisman B., Bazarsky E., Skibin A., Tam G., Chamney S., Belmaker I., et al. Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clin Diagn Lab Immunol 2004, 11(September (5)):913-918.
79. Siber G.R, Santosham M., Reid G.R., Thompson C., Almeido-Hill J., Morell A., et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 1990, 323(November (20)):1387-1392.
80. Tan P.L., Jacobson R.M., Poland G.A., Jacobsen S.J., Pankratz V.S. Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 2001, 19(March (17-19)):2434-2439.
81. Thomas C., Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology 2010, 278(December (2)):204-210.
82. Andrews N., Tischer A., Siedler A., Pebody R.G., Barbara C., Cotter S., et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ 2008, 86(March (3)):197-204.